Personalis
Dan Nicolson has extensive work experience in the biopharma and life sciences industry. Dan is currently the Director of Biopharma Business Development at Personalis, where they are involved in transforming cancer management through personalized testing. Prior to that, they worked as an Associate Director of Biopharma Business Development at Personalis.
Before joining Personalis, Dan served as a Key Account Executive at Genuity Science, where they were responsible for managing key accounts. Dan also worked as a Senior Manager of Business Development at Congenica and as a Key Account Manager in Commercial Operations at Seven Bridges Genomics.
Earlier in their career, Dan held senior positions at DNAnexus, Definiens, Oracle, and GenoLogics Life Sciences Software Inc. At Definiens, they were the Director of Business Development, involved in translational research and biomarker development. At Oracle, they served as an Application Sales Manager in the Health Sciences Global Business Unit. Dan also held the position of Director of Sales Mid-Atlantic at GenoLogics Life Sciences Software Inc.
Dan's career began at Scimagix, where they led global sales for their image informatics solution in the life science industry, working with global accounts such as Sanofi-Aventis, Merck, Roche, and Wyeth.
Dan Nicolson obtained a Bachelor of Science degree in Public Health Sciences from West Chester University of Pennsylvania in 1995. More recently, in 2020 and 2021, they completed two online certificate programs at Harvard Medical School, focused on Cancer Genomics and Precision Oncology, as well as Genetic Testing and Sequencing Technologies through the HMX Fundamentals/Pro program.
This person is not in any offices
Personalis
4 followers
Personalis is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA Million Veteran Program (MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited.